Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant - Wikidata - wikimedia - TriplyDB

Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant

Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant

http://www.wikidata.org/entity/Q35947586

about

Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors Prototype foamy virus Bet impairs the dimerization and cytosolic solubility of human APOBEC3G HIV-1 Vif, APOBEC, and intrinsic immunity APOBEC3G-UBA2 fusion as a potential strategy for stable expression of APOBEC3G and inhibition of HIV-1 replication Human cytidine deaminase APOBEC3H restricts HIV-1 replication A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity Blocking HIV-1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responses The APOBEC3 family of retroelement restriction factors Suppression of APOBEC3-mediated restriction of HIV-1 by Vif Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy APOBEC3G: an intracellular centurion Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity.In vivo HIV-1 hypermutation and viral loads among antiretroviral-naive Brazilian patients.Characterization of RNA binding and chaperoning activities of HIV-1 Vif protein. Importance of the C-terminal unstructured tail.Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification.Insights into the dual activity of SIVmac239 Vif against human and African green monkey APOBEC3G.Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity.Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers Characterization of anti-HIV activity mediated by R88-APOBEC3G mutant fusion proteins in CD4+ T cells, peripheral blood mononuclear cells, and macrophages.The HDAC6/APOBEC3G complex regulates HIV-1 infectiveness by inducing Vif autophagic degradation.APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo.Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment.Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif.Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein Host restriction factors in retroviral infection: promises in virus-host interaction.Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes.APOBEC3G impairs the multimerization of the HIV-1 Vif protein in living cells.Functional domain organization of human APOBEC3G.Differential sensitivity of "old" versus "new" APOBEC3G to human immunodeficiency virus type 1 vif.APOBEC3G-independent reduction in virion infectivity during long-term HIV-1 replication in terminally differentiated macrophages Vif and Apobec3G in the innate immune response to HIV: a tale of two proteins.APOBEC proteins and intrinsic resistance to HIV-1 infection Optimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G.

P2860

Q24565021-C9017AE8-464C-4A65-9553-E4F9E81E2C3D Q24619114-FCCFE26A-9444-473B-B5C3-082B84B3F990 Q24629953-3AFEB1D8-4355-4E55-8BFE-EFE811B31AA4 Q24647833-E1A8EE80-8064-4575-AD6B-F83C53D95627 Q24651400-8C4B29BF-F8C2-47CC-BB85-0CBE64350502 Q24653682-52344A67-02BC-4823-8632-0982258AA4FE Q24656551-CFD0B498-8111-47AD-88C6-70B4A28C8CE6 Q26774878-4E9F421B-4CB1-420B-973C-6838CD1EF4C2 Q26862780-D98952E5-0415-4B77-A9F8-AD8FA41F0EC3 Q27025150-D46F00AE-8E86-4562-A2DC-C9C739453637 Q28480578-819D3B78-C650-47C5-82DF-6B5B0CB62A29 Q28754989-581AD856-B39F-4C1D-88D0-6A8445B5D026 Q33328499-17D2FE4D-C9D3-4255-8C0B-59BF266ECE0D Q33349452-31B7884F-A089-4D2A-B198-07A0239622DD Q33654949-7A326EBE-60A1-44F1-8CFA-7395FEBD78E4 Q33826857-30B891ED-9ABB-4029-9D0B-07758377112F Q34045987-AE15A584-B27D-47EB-9AE4-ADC7CEF8756F Q34116867-6AC5183A-8C12-4A78-903F-46FB19B801C2 Q34266485-0D137386-72EB-44AA-9539-33ACAB63D71A Q34412763-2C155F2F-2D9E-4B9C-8485-390A09A006DC Q34493717-5214857B-AA1C-40C2-9CEC-1E439CB73248 Q34742607-41478B96-6D7B-48F3-970A-727E078E062A Q35489088-0686E819-B1B1-46D4-92CC-45FC613EDC71 Q35496476-6E853FE9-92F2-4D9A-ACC9-BD8A51B4753B Q35776289-937CEC8E-BE9C-465C-BA92-8A41953C803D Q36019696-EFB47E8A-F060-49D4-8E4F-BC8813FB1BBB Q36156679-917048ED-8B0C-41AA-BF3F-3C055B25DD5F Q36249419-F99B8F41-886D-4FB6-83E7-37F9CAEA707C Q36315163-E0195F6D-450E-4435-8AED-2D9C628E5187 Q36432758-EA2D8D98-9E76-4B36-8311-C91329521343 Q36548179-FC180A81-D61F-4A20-AB32-C21E28DAA3E4 Q36666251-C77A52DD-2393-4F89-874E-AED72E5309E1 Q36677709-A50F616A-B85F-472C-8378-82E4C7A8E9D7 Q36827236-A48D679B-EB2E-4DEA-8EF0-53B38B55964B Q37012852-B756499F-F060-4DD5-9772-53ED83A268C5 Q37033381-8842BA3B-6673-4911-9CEC-679B3F1D58B4 Q37039316-FD14117B-5047-4119-8864-DE45F8448088 Q37119030-FCB964FE-EC7C-4CEB-9F69-119FFF446AAC Q37140468-945A8BED-5B59-4F99-B288-5ACDD9B8C3DF Q37191968-C62B0F71-E360-4604-A4C4-461895E3483E

P2860

Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant

http://www.wikidata.org/entity/Q35947586

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Human immunodeficiency virus t ...... ion-resistant APOBEC3G variant

@ast

Human immunodeficiency virus t ...... ion-resistant APOBEC3G variant

@en

type

label

Human immunodeficiency virus t ...... ion-resistant APOBEC3G variant

@ast

Human immunodeficiency virus t ...... ion-resistant APOBEC3G variant

@en

prefLabel

Human immunodeficiency virus t ...... ion-resistant APOBEC3G variant

@ast

Human immunodeficiency virus t ...... ion-resistant APOBEC3G variant

@en

P1433

Q35947586-5C6371A6-DE45-4C08-92AC-EEB3438420D2

P1476

Q35947586-A7E59E2B-A491-4D4D-A885-FF17153C698E

P2093

Q35947586-0C752BDD-2699-4408-B75F-EE8F448DC908

Q35947586-456F91D1-00AF-41A2-8BF3-78D745467ABF

Q35947586-4806C16A-E634-4F22-B14B-CC9E7FE4AAE2

Q35947586-6627B656-37DB-4F04-A0E7-4F73D5CEA50A

Q35947586-664ADF37-62FB-4B51-A9F7-40B738CF9BC0

Q35947586-9716BE8A-9899-4CD1-AF2A-1130322B901B

Q35947586-AC82FAAD-4DBE-49CB-AD38-637A55DC0913

P2860

Q35947586-01FB7D55-E200-448F-9059-CB0D21B38D85

Q35947586-043C3BC0-090F-4E50-A737-408AF156DC3D

Q35947586-048095D2-416A-4F8D-A089-E7365F2BB98B

Q35947586-1E12749E-803C-44CD-B542-D0EE68B501B9

Q35947586-22AF36AE-08CE-4AD9-B866-7DF567D38A94

Q35947586-230CDF1B-AA69-427E-B77E-E3E11E6EB250

Q35947586-2422B811-FA10-447C-8BBF-D812CD50ED3F

Q35947586-2B50BB67-67F8-4660-8E20-41E89A6FFEA7

Q35947586-2C6ECE66-D8E1-4C3B-885E-064D2A56C843

Q35947586-2F74FAEF-79B5-4E8C-A666-E88F583251FB

P304

Q35947586-52ADD7B2-2477-47A7-BBF8-F3C0EE4E8E3E

P31

Q35947586-9D52BEE8-A4DD-40C9-A13F-C1BDC2F3DC97

P356

Q35947586-D81B6637-E1A0-46EF-8F15-6CE281D62DC1

P407

Q35947586-49FB8A17-5D02-4435-B894-2A5FCE9BF056

P433

Q35947586-50EFEE33-0648-4F5D-B281-81002D89C603

P478

Q35947586-DEA599A1-24BB-48C2-B15C-8BC7D7043D92

P577

Q35947586-959493F6-8773-4CF5-9CEE-67104E18A9C3

P698

Q35947586-288D8A7C-91C3-45C5-B14D-AC9F65212099

P932

Q35947586-483EE241-79A1-4604-8A30-92FBC080C459

P356

P1433

Journal of Virology

P1476

Human immunodeficiency virus t ...... ion-resistant APOBEC3G variant

@en

P2093

Eri Miyagi

http://www.w3.org/2001/XMLSchema#string

Hiroaki Takeuchi

http://www.w3.org/2001/XMLSchema#string

Klaus Strebel

http://www.w3.org/2001/XMLSchema#string

Mohammad A Khan

http://www.w3.org/2001/XMLSchema#string

Ritu Goila-Gaur

http://www.w3.org/2001/XMLSchema#string

Sandra Kao

http://www.w3.org/2001/XMLSchema#string

Sandrine Opi

http://www.w3.org/2001/XMLSchema#string

P2860

Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies

An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22

The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA

Dimeric structure of a human apolipoprotein B mRNA editing protein and cloning and chromosomal localization of its gene

A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins

A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion

Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication

Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

DNA deamination mediates innate immunity to retroviral infection

P304

8236-8246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.02694-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P577

2007-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17522211

http://www.w3.org/2001/XMLSchema#string

P932

1951302

http://www.w3.org/2001/XMLSchema#string